Onconetix Inc (ONCO)

[The Night Stalker]

looks good

[81vette]

Today’s conference presentation 2:30pst /11:30est ,so many pipelines on new,desperately needed vaccines,bright future,huge merger/acquisition candidate too

[81vette]

scanner says>institutional buying up 63.58% (5th highest in big boards)

[81vette]

17.3% insider ownership,try and find a pharma with more skin in the game,i cant,they believe big things coming with their own $

[81vette]

buy signals on scanner>New CCI Buy Signals,Moved Above Upper Bollinger Band,P&F Double Bottom Breakout,also 50%of daily ave vol.in 15min (multiple Xs ave vol gets attention,many ppl just scan for vol.)

[81vette]

institutional backing/buying is key>https://ih.advfn.com/stock-market/NASDAQ/blue-water-vaccines-BWV/stock-news/89757155/blue-water-vaccines-announces-institutional-resear

[81vette]

$490,000 traded today,follow the $ ,pps will

[81vette]

--Maxim Starts Blue Water Vaccines at Buy With $4 Price Target,09:40 AM EST, 12/08/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

[81vette]

nhod into close,volume increasing,institutional buying,following the $ here into after-mkt/pre-mkt should be interesting with this ss

[81vette]

630k shares short(squeezing),10M float,Shares Outstanding 14.34M,Institutional Ownership 20.50%,Insider Ownership 17.30%,this is going big with this ss,watch for short available to decline,could be another epic short squeeze 1000%winner with what is in pipeline

[81vette]

conference today>Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children’s Hospital Medical Center, St. Jude Children’s Hospital, and The University of Texas Health San Antonio. The Company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children, and prevention of pneumonia in older people at risk for contracting pneumococcal pneumonia, a significant unmet medical need. The advantage of this technology includes a serotype independent mucosal immunity that prevents colonization in the upper respiratory tract as well as systemic immunity that can confer serotype independent against invasive pneumococcal disease. The Company is also developing a Chlamydia vaccine candidate with UT Health San Antonio to prevent infection and reduce the need for antibiotic treatment associated with contracting Chlamydia disease.

[Backstabbed]

$BWV - What’s up peeps! Let’s see what happens on Wednesday! Picked up a starter today!

[subslover]

https://www.marketscreener.com/quote/stock/BLUE-WATER-VACCINES-INC-133576962/news/Blue-Water-Vaccines-Announces-Exclusive-Global-License-Agreement-for-Chlamydia-Vaccine-Candidate-De-42375400/

[subslover]

https://www.marketscreener.com/quote/stock/BLUE-WATER-VACCINES-INC-133576962/news/Blue-Water-Vaccines-Announces-Exclusive-Global-License-Agreement-for-Chlamydia-Vaccine-Candidate-De-42375400/

[subslover]

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

https://www.benzinga.com/pressreleases/22/11/g29658486/blue-water-vaccines-reports-third-quarter-2022-financial-results-and-recent-business-highlights-an

[StockLogistics]

Chance for surge here with news imo

[StockLogistics]

Reversal higher may have occurred on chart, lots of potential

[StockLogistics]

“12:49p ET 8/18/2022 - Dow Jones
Blue Water Vaccines Down 38% After Wednesday Surge


By Josh Beckerman

Blue Water Vaccines Inc. shares were down 38% at $4.74, a day after nearly tripling on news that the company is exploring use of its virus-like particle platform for a monkeypox vaccine candidate.

The stock closed at $2.55 Tuesday and $7.64 Wednesday.

Blue Water's operations include development of a universal flu vaccine to provide protection from all virulent strains. When it reported second-quarter results on Monday, the company said it believes its cash and cash equivalents are sufficient to fund operations through 2024.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

August 18, 2022 12:49 ET (16:49 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.”

[StockLogistics]

BWV was 68 dollars a share 7 months ago, now it is 1.50. Talk about a discount for an active company with a product(s). For so many pharma and small cap tech the market not too long ago thought the fair value was 90% higher than a lot of companies are assessed at today,
And the companies are actually in a better clinical/technological position today, and this being down 90% is truly incredible so many companies with favorable charts right now and the market is trading scared.

[StockLogistics]

“9:20a ET 10/11/2022 - Benzinga
Blue Water Vaccines Announces Plans To Evaluate Efficacy Of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At The World Vaccine Congress In Barcelona

Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced plans to investigate the ability of BWV-201, a Streptococcus pneumoniae vaccine candidate for acute otitis media ("AOM") prevention, to also protect against non-invasive pneumococcal pneumonia at the World Vaccine Congress in Barcelona.

While Streptococcus pneumoniae is commonly found in the nose and throat of healthy individuals, overgrowth and spread of the bacteria can result in pneumococcal disease. Non-invasive forms of pneumococcal disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis. BWV's new development plan aims to assess the efficacy of BWV-201 in protecting individuals against non-invasive pneumococcal pneumonia.

BWV-201 is a live attenuated bacterial vaccine candidate developed for the prevention of AOM in children caused by Streptococcus pneumoniae. New data, based on experiments at St. Jude Children's Research Hospital, suggests that BWV-201 may also provide protection against pneumococcal pneumonia by limiting the ability of Streptococcus pneumoniae to infect the lungs.

While conjugate and polysaccharide vaccines are available to protect against pneumococcal disease, protection is mainly limited to invasive disease. Efficacy rates of these vaccines against pneumococcal pneumonia are historically only between 0% and 50%, as these vaccines are administered intramuscularly and elicit a strong systemic response, but poor protection at the mucosal surface where pneumonia infection begins. Additionally, these vaccines only provide protection against serotypes included in the vaccine, ranging from 13 to 23 serotypes. By administering the modified live bacteria intranasally, BWV-201 is designed to elicit a strong mucosal immune response, regardless of capsular polysaccharide serotype.

"While current pneumococcal vaccines have demonstrated excellent efficacy against invasive pneumococcal disease historically, pneumococcal pneumonia remains a significant unmet medical need," said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. "With this new data, we believe our vaccine can provide protection across all Streptococcus pneumoniae strains and eliminate the need for antibiotic treatment associated with pneumococcal pneumonia. We are excited to further develop BWV-201 for this new indication and look forward to addressing this need."

According to the Centers for Disease Control and Prevention, non-invasive pneumococcal pneumonia causes an estimated 150,000 hospitalizations each year in the United States alone. Despite vaccination efforts with traditional pneumococcal vaccines, the American Lung Association reports that adults over 65 years old are at 6.1 times greater risk for pneumonia infection and over 10 times more likely to be hospitalized with pneumococcal pneumonia versus healthy adults.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

Gap filled at 1.71, big chance to go higher now because of that and the charts imo

[StockLogistics]

“This prospectus relates to the offer and resale of up to an aggregate of 8,876,705 shares of common stock, par value $0.00001 per share (“Placement Shares”), of Blue Water Vaccines Inc. (“Blue Water,” “BWV,” “the Company,” “we,” “us” or “our”) held by selling stockholders, consisting of (a) 1,350,000 Placement Shares, (b) 220,997 Placement Shares (“Wainwright Warrant Shares”) issuable upon exercise of the warrants (the “Wainwright Warrants”) issued to H.C. Wainwright & Co., LLC, or its designees, in a private transaction on August 22, 2022 (the “Private Placement”), (c) 2,333,280 Placement Shares (“Prefunded Warrant Shares”) issuable upon exercise of the pre-funded warrants (the “Prefunded Warrants”) issued to the selling stockholders in the “Private Placement” determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration rights agreement and (d) 4,972,428 Placement Shares (“Preferred Investment Option Shares,” together with the Prefunded Warrant Shares, the “Warrant Shares”) issuable upon exercise of the preferred investment options (the “Preferred Investment Options”, together with the Prefunded Warrants, the “Warrants”), issued to the selling stockholders in the Private Placement determined as if the outstanding Preferred Investment Options were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement, all of which were acquired by the selling stockholders in. The holders of the Placement Shares, the Warrant Shares and the Warrants are each referred to herein as a “Selling Stockholder” and collectively as the “Selling Stockholders.”
This prospectus also covers any additional shares of common stock that may become issuable upon any anti-dilution adjustment pursuant to the terms of the Warrants issued to the Selling Stockholders by reason of stock splits, stock dividends, and other events described therein.
The Selling Stockholders, or their respective transferees, pledgees, donees or other successors-in-interest, may sell the Placement Shares or the Warrant Shares through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Stockholders may sell any, all or none of the securities offered by this prospectus, and we do not know when or in what amount the Selling Stockholders may sell their Placement Shares or Warrant Shares hereunder following the effective date of this registration statement. We provide more information about how a Selling Stockholder may sell its Placement Shares or Warrant Shares in the section titled “Plan of Distribution” on page 165.
We are registering the Placement Shares and Warrant Shares on behalf of the Selling Stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale of our common stock by the Selling Stockholders in the offering described in this prospectus. We cannot predict when and in what amounts or if the Warrants will be exercised. We have agreed to bear all of the expenses incurred in connection with the registration of the Placement Shares and the Warrant Shares. The Selling Stockholders will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of the Placement Shares and the Warrant Shares.
We are an “emerging growth company” and a “smaller reporting company” as such terms are defined under federal securities laws, and, as such have elected to take advantage of certain reduced public company reporting requirements for this prospectus and may elect to do so in future filings.
This prospectus describes the general manner in which the Placement Shares and the Warrant Shares may be offered and sold.
If necessary, the specific manner in which the Placement Shares and the Warrant Shares may be offered and sold will be described in a supplement to this prospectus.
Our shares of common stock have experienced extreme volatility in market prices and trading volume since listing. From February 18, 2022 (the date our shares were initially listed on Nasdaq) to the date hereof, the market price of our common stock has fluctuated from an intra-day low on Nasdaq of $1.80 on July 15, 2022 to an intra-day high of $90.90 per share on February 22, 2022. By comparison, our initial public offering, which closed on February 23, 2022, was conducted at $9.00 per share. During this time, we have made six announcements regarding certain research developments and partnerships for our vaccine candidates. Notwithstanding the foregoing, since our initial public offering on February 18, 2022, there were no material recent publicly disclosed changes in the financial condition or results of operations of the Company, such as our earnings or revenue, that are consistent with or related to the changes in our stock price. The trading price of our common stock has been, and may continue to be, subject to wide price fluctuations in response to various factors, many of which are beyond our control, including those described under the heading “Risk Factors” beginning on page 14 of this prospectus.
Investing in our common stock involves a high degree of risk. Please read “Risk Factors” beginning on page 14 of this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is September 19, 2022
”

[subslover]

Love the happy face!! :_}

[ErnieBilco]

Seems kind of stupid to bring on a new director with a UK set of credentials instead of doctors or scientists.

This is supposed to be a vaccine company right?

Looks like Hernandez is preparing to dump the sht out of shares with a new Deloitte hasbeen on board.

[ErnieBilco]

Is it safe to reprice my $1000 a share bid or is it still gonna happen?

[INFINITI]

What’s going on here why the significant drop

[kid70]

Looking much better

[PStockPickz]

Looking good now

[kid70]

Yep

[INFINITI]

I might just get back in

[INFINITI]

For a min lol

[kid70]

Looking good here thus morning

[INFINITI]

Check out PSTV

[INFINITI]

Yes after a hard run it will have to consolidate

[kid70]

So far a mistake fo holding over night. Hopefully it turns around.

[INFINITI]

If it drops believe $5 Il get back in observing

[subslover]

If you wake up very early like 6 am est you can catch these babies before the big run. Buy pre-market and start peeling once up 100% and more. Like taking candy from a baby!

[PStockPickz]

* I

[PStockPickz]

Haha good day . Need to learn to let these ride up until the close. They seem to be consistent

[subslover]

What a ride huh? Misplaced my motion sickness pills. lol. :)

[mrinvestor08]

Indeed

[kid70]

Nope.still holding. Going to see. What tomorrow brings

[INFINITI]

Gl the volatility is crazy

[mrinvestor08]

Bought some 6.30s in AH trading

[INFINITI]

Hope everyone took profits at close gl

[INFINITI]

Beast enjoy!!!!

[PStockPickz]

Damn still going

[Invest-in-America]

THANK YOU, for that correction, Sir!!!

[Invest-in-America]

You'll be very HAPPY, Sir, at the Close today!!! NICE PICK!!!

[INFINITI]

It should break $5 just saying GL

[Invest-in-America]

Hey, Infinity, Dude!! You picked the MONSTER RUNNER of the WEEK, behind THIS one, Bro!!! CONGRATS on a glorious scale. (I'm still CRYING like a baby, because I ignored this one!!!)

What's that old proverb about a, "Fool & his money"???